National Taiwan University

Nano Targeting & Therapy Biopharma Inc.

National Science Council

Academia Sinica

National Health Research Institutes

Scinopharm Taiwan, Ltd.

Chinese Petroleum Corporation

Chan, Hardy Wai Hong

Chung-Yuan Mou

Si-Han Wu

Yi-Ping Chen

Cheng-Hsun Wu

Hong-Ping Lin

Jingling Yang

Shoa-Lin Lin

Hardy Wai Hong Chan

Chung-Shi Yang

Kuo-Lun Tung

Sunney Ignatius Chan

Leu-Wei Lo

Sheng-Fa Yu

Ping-Yu Chen

Chia-Hung Lee

Geng-Sheng Lin

Rong-Lin Zhang

Rong-lin Zhang

Tien-Chun Yang

Heng-Liang Wu

Chih-Cheng Liu

Ravirala Ramu

Suman Maji

Penumaka Nagababu

Nai-Yuan Kou

Yi-ping Chen

The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.

Drug-loaded mesoporous silica nanoparticle for prevention and treatment of brain cancers or brain metastases

The present disclosure relates to a field of hollow silica nanospheres. Particularly, the present disclosure relates to silica nanoparticles as adjuvant to induce or enhance immune response or as carrier to deliver antigen to a body.

Silica nanosphere for immunotherapy

The disclosure provides a method for delivering an agent to posterior segment of an eye comprising administrating a pharmaceutical composition comprising the agent and mesoporous silica nanoparticles to the eye. An eye drop and a method for treating an ocular disease in a subject in need of such treatment are also provided.

Method for delivering an agent to posterior segment of an eye and uses thereof

Methods of fabricating a porous membrane are disclosed. The first method includes the following operations. A mesoporous silica thin film with perpendicular mesopore channels is grown on a polymer film. The mesoporous silica thin film and the polymer film are transferred onto a macroporous substrate, in which the polymer film is positioned between the macroporous substrate and the mesoporous silica thin film. The polymer film is removed to form the porous membrane. The second method includes the following operations. A polymer film is formed on a macroporous substrate, wherein the polymer film includes crosslinked polymers including cross-linked polystyrene, cross-linked polymethyl methacrylate, or a combination thereof. A mesoporous silica thin film with perpendicular mesopore channels is grown on the polymer film. The polymer film is removed to form the porous membrane.

Methods of fabricating porous membrane

Silica-based biomolecule carriers, compositions comprising the same and preparation methods and uses thereof for delivering biomolecules into a cell are provided. The silica-based biomolecule carrier comprises a porous core; a first bioactive moiety; a second bioactive moiety functionally associated with the first bioactive moiety; and linkers for respectively conjugating the first bioactive moiety and the second bioactive moiety to the porous core.

Silica-based biomolecule carrier, pharmaceutical composition comprising the same, preparation method and use thereof

The present disclosure relates to mesoporous silica nanoparticles (MSNs) with specific modifications as drug delivery systems containing both tumor targeting and blood-brain barrier (BBB) penetration properties suitable for cancer treatment and/or CNS disease treatment. The present disclosure also relates to method of preparing MSNs and the MSNs prepared by the method as described herein.

Surface-modified mesoporous silica nanoparticle for blood-brain barrier penetration,tumor targeting and cancer metastasis treatment, methods of production and uses thereof

A battery and a method of fabricating a porous membrane are disclosed. The battery includes an anode, a cathode, and a battery separator. The battery separator is positioned between the anode and the cathode and includes a macroporous substrate and a mesoporous silica thin film (MSTF) with perpendicular mesopore channels. The MSTF is positioned on the macroporous substrate. The method includes the following steps. A polymer film is formed on a macroporous substrate. A MSTF with perpendicular mesopore channels is grown on the polymer film. The polymer film is removed to form the porous membrane.

Battery having separator including mesoporous silica thin film positioned on macroporous substrate

The present invention relates to hollow silica nanoparticles as a drug delivery system loading bioactive ingredients. Particularly, the present invention relates to silica nanoparticles comprising multi-layered silica shells with one or more bioactive ingredients encapsulated within and their applications in drug delivery; and processes of preparing the same.

Hollow silica nanoparticles with encapsulated bioactive ingredients, preparation process and applications thereof

This invention relates to molecular catalysts and chemical reactions utilizing the same, and particularly to molecular catalysts for efficient catalytic oxidation of hydrocarbons, such as hydrocarbons from natural gas. The molecular catalytic platform provided herein is capable of the facile oxidation of hydrocarbons, for example, under ambient conditions such as near room temperature and atmospheric pressure.

Molecular catalysts capable of catalyzing oxidation of hydrocarbons and method for oxidizing hydrocarbons

A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si&#x2014;OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si&#x2014;OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.

Charged mesoporous silica nanoparticle-based drug delivery system for controlled release and enhanced bioavailability

The present invention relates to a method for synthesizing mesoporous aluminosilicate or pure-silica molecular sieves with newly hierarchical morphologies by adding suitable amount of alcohol. There are hollow sphere, hollow sphere with a pillar in it and solid sphere by adjusting the Al,O,/SiO,and tetraethylorthosilicate/SiO,ratio. The wall of the micron-sized spherical structure consisted of well-ordered cylindrical pores of nanometer size. The dimensions and the morphologies of the mesoporous structure are adjustable by varying the reaction components as the water content, the silicon/surfactant ratio and the reaction and the hydrothermal temperature.

Control of morphology of mesoporous aluminosilicate or pure-silica molecular sieves by effect of alcohol

The present invention relates to a method for synthesizing mesoporous aluminosilicate and pure silica molecular sieves of new micro-tubular morphology. The wall of the microtubules contains coaxial cylindrical pores of nanometer size. The diameter of the hollow tubular is adjustable from 0.1 to 3 micrometer by varying the reaction conditions such as the surfactant/water ratio, the addition of salts or cosurfactants, the surfactants with different carbon chain length and the silicon/aluminum ratio.

Mesoporous aluminosilicate molecular sieves having

An echo contrast agent for use in echocardiography is disclosed which can be introduced into the body through peripheral venous injection to opacify left ventricle. The echo agent to be injected into the body contains a plurality of gas-in-liquid microbubbles which are smaller than red blood cells and can therefore traverse the pulmonary circulation to reach the left ventricle in substantial quantity to effectuate opacification thereof. The echo contrast agent disclosed in this invention contains: (a) an aqueous solution containing 0.40-0.60 grams of albumin and 4.0-10.0 grams of glucose per 10 ml solution mixed with (b) glycerin. The ratio between (b) and (a) should be no less than 0.050. A method for preparing this echo contrast agent was also disclosed.

Growing community of inventors

Taipei, Taiwan

Chung-Yuan Mou